Coya Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Coya Therapeutics, Inc. (COYA) reported Increase (Decrease) in Deferred Revenue of -$494.89 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-11
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$243.75K.
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$251.15K.
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $240.00K.
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $635.75K.
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was $454.25K, a 53.49% increase from fiscal 2024.
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $295.94K, a 80.24% decline from fiscal 2023.
- Coya Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was $1.50M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$243.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$494.89K 10-Q · filed 2026-08-11 | -$254.89K derived: sum of 3 quarters · filed 2026-08-11 | $380.86K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$251.15K 10-Q · filed 2026-05-12 | -$11.15K derived: sum of 2 quarters · filed 2026-05-12 | $624.60K derived: sum of 3 quarters · filed 2026-05-12 | $460.98K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $875.75K derived: sum of 2 quarters · filed 2026-03-16 | $712.13K derived: sum of 3 quarters · filed 2026-08-11 | $454.25K 10-K · filed 2026-03-16 |
| 2025-09-30 | $635.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $472.13K derived: sum of 2 quarters · filed 2026-08-11 | $214.25K 10-Q · filed 2025-11-12 | $212.29K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$163.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$421.50K 10-Q · filed 2026-08-11 | -$423.45K derived: sum of 3 quarters · filed 2026-08-11 | -$423.45K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$257.88K 10-Q · filed 2026-05-12 | -$259.84K derived: sum of 2 quarters · filed 2026-05-12 | -$259.84K derived: sum of 3 quarters · filed 2026-05-12 | $164.89K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.95K derived: sum of 2 quarters · filed 2026-03-16 | $422.78K derived: sum of 3 quarters · filed 2026-03-16 | $295.94K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $424.73K derived: sum of 2 quarters · filed 2025-11-12 | $297.89K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $424.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $297.89K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$126.84K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $1.50M 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |